MiMedx Group Inc (MDXG) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of MiMedx Group Inc $8.93, price $4.77, upside +87.2%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MiMedx Group Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $2.63 – $15.83 · fair‑value band $6.20 – $11.61 · the $4.77 price screens below the $8.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow MiMedx Group in your weekly email
Every Wednesday you see whether MiMedx Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Show more
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Stock analysis
MiMedx Group Inc (MDXG) currently trades at $4.77, while our model-based Fair Value estimate is $8.93, implying the stock looks roughly 46.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $11.31 per share, and 20 of the 24 models we run sit above the $4.77 price.
Bear case: the Asset-Based group reads lowest at $1.15, and 4 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $6.20 (bear) to $11.61 (bull), the price of $4.77 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
MiMedx Group Inc reported revenue of $419M in FY2025 versus $242M in FY2021, a compound +14.7%/yr. Reported net income was $48.6M in FY2025.
Key figures
Market cap $714M · P/E ratio 23.9 · P/S ratio 2.77 · EPS (TTM) $0.2000 · Net margin 11.6% · Return on equity 13.8% · Return on assets (EBIT) 8.8% · Operating margin −27.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).
What moves the price
The share trades about 40% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 87%, MDXG screens cheaper than that median.
Fair Value models
Bear $6.20Fair Value $8.93Bull $11.61
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1463 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+20.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +8.4% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+38.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+38.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 15%
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−0.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −4.6% a year for the price and −3.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside+87% · Top 25%
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)8% · Above median
Operating margin (TTM)−27% · Bottom 25%
Growth and dividend
Revenue growth−33% · Bottom 25%
Balance sheet
Debt / equity0.06× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MiMedx Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/MDXG
Frequently asked questions
Is MiMedx Group Inc (MDXG) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $8.93 versus a price of $4.77, about +87% upside (undervalued).
What is the fair value of MDXG?
Our model-based fair value for MiMedx Group Inc is $8.93 (as of Sep 23, 2026), built from audited fundamentals. The current price: $4.77.
What is the quality score of MDXG?
MiMedx Group Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MiMedx Group Inc (MDXG)?
Our model-based price target is the fair value of $8.93 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $6.20, optimistic scenario $11.61. It is a calculation from audited fundamentals, not an analyst target.
What is the MiMedx Group Inc stock forecast for 2026?
Our models put fair value at $8.93, about +87% upside versus a price of $4.77 (undervalued). Cautious scenario $6.20, optimistic scenario $11.61. The calculation is refreshed regularly with new filings.
What is the revenue of MiMedx Group Inc (MDXG)?
MiMedx Group Inc reported trailing-twelve-month revenue of about $389M (latest available figure, as of Sep 23, 2026).
What growth is priced into MiMedx Group Inc (MDXG)?
For today's price to be fair in a discounted-cash-flow model, MiMedx Group Inc would have to grow free cash flow by -2.3 % per year for five years (discount rate 12.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of MDXG use?
Our models discount MiMedx Group Inc at 12.5 %: a base by market capitalisation (small), damped by beta 1.46, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MiMedx Group Inc that is -2.3 % per year a year over ten years, using the same discount rate (12.5 %) and the same formula as our fair value.
How much growth has MiMedx Group Inc (MDXG) delivered so far?
Over the past 5 years revenue at MiMedx Group Inc grew +11.0 % a year. The price currently implies -2.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MiMedx Group Inc (MDXG) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into MiMedx Group Inc (-2.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MiMedx Group Inc (MDXG)?
The free-cash-flow yield on the price is 10.22 %: that much free cash flow MiMedx Group Inc produces per unit of market value. When it exceeds the discount rate of our models (12.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MiMedx Group Inc (MDXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MiMedx Group Inc it is $8.93 per share (as of Sep 23, 2026), against a price of $4.77. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is MiMedx Group Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, MDXG trades below its calculated fair value: price $4.77, fair value $8.93, a gap of about +87% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDXG?
No. The price is what the market pays today ($4.77); the fair value is what the company's own numbers justify ($8.93). For MiMedx Group Inc the two are $4.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is MiMedx Group Inc worth?
The market values MiMedx Group Inc at about $714M (market capitalisation, as of Sep 23, 2026). Per share that is $4.77; our models calculate a fair value of $8.93 per share.
What do the bullish and bearish scenarios say about MDXG?
Our models span a range for MiMedx Group Inc: cautious scenario $6.20, base $8.93, optimistic $11.61 per share (as of Sep 23, 2026, price $4.77). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MDXG?
MiMedx Group Inc trades at a price-to-earnings ratio of 23.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.93 is built from several models across several years. Other multiples: PEG 2.9, P/B 2.8, P/S 1.8, EV/EBITDA 10.7.
What is the PEG ratio of MDXG?
The PEG ratio of MiMedx Group Inc is 2.88 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of MiMedx Group Inc (MDXG)?
Balance-sheet figures for MiMedx Group Inc (as of Sep 23, 2026): return on equity 13.8%, debt of 0.06 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is MDXG from its 52-week high?
MiMedx Group Inc trades at $4.77, about 40% below its 52-week high of $7.96 and 54% above the low of $3.09 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $8.93 is for.
Which stocks are comparable to MiMedx Group Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MiMedx Group Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $4.77, calculated fair value $8.93 (+87%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MDXG calculated?
We run MiMedx Group Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. MiMedx Group Inc currently trades 87 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MiMedx Group Inc (MDXG)?
The closing price on Sep 23, 2026 was $4.77. Our model-based fair value is $8.93, about +87% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MiMedx Group Inc right now?
The price is below even our cautious bear case ($6.20). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($6.20 to $11.61) leaves room in how you read the outcome.
Where does the earnings growth of MiMedx Group Inc (MDXG) come from?
Earnings per share at MiMedx Group Inc grew +10.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin +10.7 %, tax rate +0.7 %, residual (interest, one-offs) −5.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of MiMedx Group Inc
How large is the market capitalisation of MiMedx Group Inc (MDXG)?
The market capitalisation of MiMedx Group Inc is $714M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MiMedx Group Inc (MDXG)?
The price-to-sales ratio of MiMedx Group Inc is 2.77 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MiMedx Group Inc (MDXG)?
Earnings per share at MiMedx Group Inc are $0.2000 (price ÷ EPS = P/E 23.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MiMedx Group Inc (MDXG)?
The net margin of MiMedx Group Inc is 11.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MiMedx Group Inc (MDXG)?
The return on equity (ROE) of MiMedx Group Inc is 13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MiMedx Group Inc (MDXG)?
On an EBIT basis the return on assets of MiMedx Group Inc is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MiMedx Group Inc (MDXG)?
The operating margin of MiMedx Group Inc is −27.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MiMedx Group Inc (MDXG)?
Revenue at MiMedx Group Inc is growing −33.1% versus a year earlier (3y avg +16.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MiMedx Group Inc (MDXG)?
Earnings per share at MiMedx Group Inc are growing +99.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does MiMedx Group Inc (MDXG) hold?
MiMedx Group Inc holds more cash than debt, $144M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch MiMedx Group Inc in the live analysis
One click puts MiMedx Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 23, 2026